Chloroquine diphosphate
Names
[ CAS No. ]:
50-63-5
[ Name ]:
Chloroquine diphosphate
[Synonym ]:
MFCD00069852
acide phosphorique - N-(7-chloroquinoléin-4-yl)-N,N-diéthylpentane-1,4-diamine (2:1)
Chloroquine phosphate
7-Chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline Diphosphate
EINECS 200-055-2
N-(7-chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine bis(phosphate)
N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine phosphate (1:2)
N-(7-Chloro-4-quinolinyl)-N,N-diethyl-1,4-pentanediamine phosphate (1:2)
N4-(7-Chloro-4-quinolyl)-N1,N1-diethyl-1,4-pentanediamine Diphosphate
Chloroquine diphosphate salt
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline phosphate (1:2)
Aralen phosphate
1,4-Pentanediamine, N-(7-chloro-4-quinolinyl)-N,N-diethyl-, phosphate (1:2)
1,4-pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-, phosphate (1:2)
N-(7-Chloroquinolin-4-yl)-N,N-diethylpentane-1,4-diamine phosphate (1:2)
Chloroquine diphosphate
Imagon
Tresochin
Chloroquinediphosphate
Malaquin
Phosphorosäure--N-(7-chlorchinolin-4-yl)-N,N-diethylpentan-1,4-diamin(2:1)
Biological Activity
[Description]:
[Related Catalog]:
[Target]
Autophagy, TLRs[1][2][3]
[In Vitro]
[In Vivo]
[Cell Assay]
[Animal admin]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Boiling Point ]:
460.6ºC at 760 mmHg
[ Melting Point ]:
200 °C (dec.)(lit.)
[ Molecular Formula ]:
C18H32ClN3O8P2
[ Molecular Weight ]:
515.862
[ Flash Point ]:
232.3ºC
[ Exact Mass ]:
515.135315
[ PSA ]:
203.30000
[ LogP ]:
3.02640
[ Storage condition ]:
Desiccate at RT
[ Water Solubility ]:
H2O: 50 mg/mL, clear
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- VB2450000
- CHEMICAL NAME :
- Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-, diphosphate
- CAS REGISTRY NUMBER :
- 50-63-5
- LAST UPDATED :
- 199606
- DATA ITEMS CITED :
- 30
- MOLECULAR FORMULA :
- C18-H26-Cl-N3.2H3-O4-P
- MOLECULAR WEIGHT :
- 515.92
- WISWESSER LINE NOTATION :
- T66 BNJ EMY1&3N2&2 IG &P2-O6
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 8571 ug/kg
- TOXIC EFFECTS :
- Gastrointestinal - nausea or vomiting Gastrointestinal - other changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 8571 ug/kg
- TOXIC EFFECTS :
- Gastrointestinal - ulceration or bleeding from duodenum Gastrointestinal - nausea or vomiting Gastrointestinal - other changes
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - child
- DOSE/DURATION :
- 250 mg/kg
- TOXIC EFFECTS :
- Behavioral - coma
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 167 mg/kg
- TOXIC EFFECTS :
- Cardiac - EKG changes not diagnostic of specified effects Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - respiratory depression
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 179 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 600 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 68 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 200 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 8 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity)
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Bird - domestic
- DOSE/DURATION :
- 64500 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 8820 mg/kg/21W-C
- TOXIC EFFECTS :
- Cardiac - other changes Liver - hepatitis (hepatocellular necrosis), diffuse Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 840 mg/kg/21D-I
- TOXIC EFFECTS :
- Behavioral - food intake (animal) Kidney, Ureter, Bladder - urine volume decreased Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 400 mg/kg/10D-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - proteinuria Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Ocular
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 72 ug/kg/12D-I
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - corneal damage
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 280 mg/kg/14D-I
- TOXIC EFFECTS :
- Behavioral - tremor Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Primate - monkey
- DOSE/DURATION :
- 1 gm/kg/10D-I
- TOXIC EFFECTS :
- Liver - fatty liver degeneration Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 1200 mg/kg
- SEX/DURATION :
- female 5-16 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 550 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - eye/ear
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 750 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 80 mg/kg
- SEX/DURATION :
- female 20-21 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - physical
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 475 mg/kg
- SEX/DURATION :
- female 10-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - physical
MUTATION DATA
- TYPE OF TEST :
- Sister chromatid exchange
- TEST SYSTEM :
- Rodent - hamster Lung
- DOSE/DURATION :
- 100 ug/L
- REFERENCE :
- CBTOE2 Cell Biology and Toxicology. (Princeton Scientific Pub., Inc., 301 N. Harrison St., CN 5279, Princeton, NJ 08540) V.1- 1984- Volume(issue)/page/year: 2,379,1986 *** REVIEWS *** TOXICOLOGY REVIEW INTEAG Internist. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1960- Volume(issue)/page/year: 15,7,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4486 No. of Facilities: 40 (estimated) No. of Industries: 2 No. of Occupations: 3 No. of Employees: 644 (estimated) No. of Female Employees: 238 (estimated)
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H302
[ Precautionary Statements ]:
P301 + P312 + P330
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xn:Harmful;
[ Risk Phrases ]:
R22
[ Safety Phrases ]:
S22-S24/25
[ RIDADR ]:
1544
[ WGK Germany ]:
3
[ RTECS ]:
VB2450000
[ Packaging Group ]:
III
[ Hazard Class ]:
6.1(b)
[ HS Code ]:
2933499090
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2933499090
[ Summary ]:
2933499090. other compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
Autophagy 10(7) , 1241-55, (2014)
Glioblastoma is one of the most aggressive human cancers with poor prognosis, and therefore a critical need exists for novel therapeutic strategies for management of glioblastoma patients. Itraconazol...
Regulators of autophagosome formation in Drosophila muscles.PLoS Genet. 11(2) , e1005006, (2015)
Given the diversity of autophagy targets and regulation, it is important to characterize autophagy in various cell types and conditions. We used a primary myocyte cell culture system to assay the role...
An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA endonuclease.Mol. Pharmacol. 87(2) , 323-37, (2015)
The influenza virus PA endonuclease, which cleaves capped cellular pre-mRNAs to prime viral mRNA synthesis, is a promising target for novel anti-influenza virus therapeutics. The catalytic center of t...